

A SIMPLE AND RAPID RADIOIMMUNOASSAY OF TRIIODOTHYRONINE IN UNEXTRACTED SERUM

Bhartur N. Premachandra

Veterans Administration Hospital, Jefferson Barracks and Washington University, St. Louis, Missouri

A simple, accurate, and rapid procedure for radioimmunoassay (RIA) of triiodothyronine (T_3) is described. Serum is denatured by sodium trichloroacetate and the T_3 released is allowed to react with ^{125}I - T_3 -labeled T_3 antiserum. The displaced ^{125}I - T_3 is rapidly taken up by an anionic-resin sponge, and this uptake is linearly related to serum T_3 concentration. The entire assay procedure was completed in the same tube in about 1 hr. The T_3 antibody was specific, and T_4 -to- T_3 conversion in the assay did not occur. Recovery of exogenously added T_3 was virtually complete. The mean T_3 concentration in 92 euthyroid subjects (142 ng/100 ml) is comparable to the values described in a number of radioimmunoassays for T_3 .

The usefulness of triiodothyronine (T_3) along with thyroxine (T_4) measurement for proper clinical assessment of thyroid function and for other physiologic and metabolic thyroid studies has underscored the significance of serum triiodothyronine determination in man (1). Determination of T_3 by radioimmunoassay (T_3 -RIA) is the only practical way, as the alternative procedures (gas chromatography, saturation analysis after separating T_3 and T_4 by chromatography, etc.) are too involved for routine use and might even be misleading. Hence, new T_3 -RIA procedures have been continually appearing (2-15). Many of these T_3 -RIAs, however, entail time-consuming and cumbersome details; in addition, to eliminate interference from thyroxine-binding globulin (TBG), blocking agents must be employed and such an approach may not be altogether satisfactory (12,16).

We recently described a simple and rapid procedure for T_4 -RIA that did not employ TBG-blocking agents; instead, sodium trichloroacetate was used to denature serum and extract T_4 , and anionic-resin

sponges permitted rapid separation of bound and unbound hormone (17). Substituting T_3 antiserum for T_4 antiserum in essentially the same assay system affords an equally simple T_3 -RIA that can be completed in the same tube in about 1 hr.

MATERIALS AND METHODS

High-specific-activity ^{125}I - T_3 (590 $\mu\text{Ci}/\mu\text{g}$) was obtained from Abbott Laboratories (North Chicago, Ill.). No significant decomposition was observed within 2 weeks (by chromatography). The procedure used to conjugate T_3 with bovine serum albumin is similar to that described in detail by Oliver et al (18): 25 mg of T_3 conjugate (0.5 ml), emulsified in an equal volume of Freund's adjuvant, is injected intramuscularly in rabbits weekly for 3 weeks, and T_3 antisera are harvested 6 weeks after primary immunization. Antiserum was premixed with ^{125}I - T_3 (5 $\mu\text{g}/100$ ml), and after overnight equilibration the mixture was diluted 2000-fold (final dilution 3000) as determined from preliminary trials. Labeled antiserum (i.e., premixed with tracer amounts of ^{125}I - T_3) proved stable for 2 weeks (period tested), as shown by the superimposability of standard curves. Thyronine-free plasma was prepared as described previously (17). For preparing T_3 standards, T_3 free acid (Sigma Chemical Co., St. Louis, Mo.) was dried overnight at 40°C, and appropriate amounts in 0.25% albumin solution were then added to thyronine-free plasma to provide final T_3 concentrations of 25, 50, 100, 200, 400, 600, and 800 ng/100 ml. Then TCA-NaOH (sodium trichloroacetate diluted with enough excess NaOH to reach pH 12) was prepared by adding three parts of 0.5 N NaOH to one part 20% trichloroacetic acid.

Received Aug. 7, 1975; revision accepted Nov. 4, 1975.

For reprints contact: Bhartur N. Premachandra, V.A. Hospital, Jefferson Barracks and Washington University, St. Louis, Mo. 63125.

T₃-RIA. The principle of the technique consists in denaturing serum T₃ binding sites by TCA-NaOH; T₃ liberated from the native protein-binding sites then reacts with ¹²⁵I-T₃-labeled antibody and displaces ¹²⁵I-T₃, which is taken up by the resin sponge. This displacement (sponge ¹²⁵I-T₃ uptake) is linearly related to T₃ present in serum or standards.

Procedure. (A) First, 50 μ l of serum or T₃ standards are pipetted into polypropylene tubes (15 \times 86 mm). (B) Then 0.2 ml of TCA-NaOH solution is added to each tube, followed by shaking for 2 min. (C) Next, 0.5 ml of ¹²⁵I-T₃-labeled T₃ antiserum is added, followed by a further 2-min mixing in the automatic shaker, and the hapten-antibody mixture is allowed to equilibrate at 37°C for 30 min (final reaction mixture, pH 7.2). After equilibration, the tubes are transferred to an ice bath (0-1°C).* (D) Ten minutes after equilibration in ice bath, anionic-resin sponges (Abbott Laboratories) are introduced into each tube and squeezed with a plastic plunger (Abbott Laboratories). The radioactivity in a few tubes (usually six) is counted to represent initial activity. (E) Exactly at 30 min, sponge incubation is terminated by aspirating excess fluid, using a hollow plastic aspirator (Abbott) connected to a vacuum source through flexible tubing. The sponges are then washed three times by filling the tube with distilled water, squeezing the sponge, and aspirating the fluid each time. The washing procedure removes only bound ¹²⁵I-T₃, and unbound ¹²⁵I-T₃ abstracted into the resin sponge by ion exchange is not affected. The radioactivity in the sponge is subsequently determined (final activity). The sponge uptake of radioactivity (final activity/initial activity) is linearly related to triiodothyronine present in standards or test serum up to a concentration of 400 ng/100 ml or more, depending on assay conditions and dilution of antisera.

The T₃ extraction recovery studies were based on the rationale that, once the T₃-protein bond is effectively destroyed by TCA-NaOH, unbound T₃ would be readily abstracted by the resin sponge. Serum was labeled with ¹²⁵I-T₃ and the experimental procedure was repeated except for the addition of antibody. In control experiments, labeled test serum was replaced by ¹²⁵I-T₃-labeled gamma-globulin or labeled buffer. Then 50 μ l of ¹²⁵I-T₃-labeled serum, 50 μ l of ¹²⁵I-T₃-labeled gamma-globulin, or 50 μ l of ¹²⁵I-T₃-labeled buffer was pipetted into tubes followed by the addition of 0.2 ml of TCA-NaOH. After mixing for 2 min, 0.5 ml of phosphate buffer was added and

* Ice-bath incubation is not critical. Incubation at ambient temperature may also be carried out, provided the standards are run along with sera.

TABLE 1. EFFECT OF VARYING PERIODS OF EQUILIBRATION OF LABELED T₃ ANTISERUM WITH T₃, IN THE REACTION MIXTURE AT 37°C, ON SPONGE ¹²⁵I-T₃ UPTAKE (%) IN T₃ STANDARDS*

T ₃ standards (ng/100 ml)	Duration of Ag-Ab equilibration (min)			
	15	30	60	120
0	24.7	23.6	24.2	24.8
25	25.5	24.5	25.8	25.9
50	26.6	25.6	27.1	26.6
100	29.8	27.9	27.9	28.4
200	34.3	33.1	33.7	34.5
400	43.5	44.5	44.2	45.6
600	50.6	52.1	51.1	51.1
800	54.2	56.8	56.4	57.6
Response range between 0-800-ng standards (units)	29.5	33.2	32.2	32.8

* All values shown are means of triplicates.




FIG. 1. Representative T₃ dose-response curve.

mixed, and ¹²⁵I-T₃ uptake was determined as described.

RESULTS

When sponge ¹²⁵I-T₃ uptake was plotted against T₃ standards, a linear dose-response curve was obtained (Fig. 1). The possible effects of various factors on standard curve were investigated as follows.

Equilibration (at 37°C) of ¹²⁵I-T₃-labeled antiserum with T₃ in the reaction mixture. Results are given in Table 1. From the similarity of ¹²⁵I-T₃ uptake values corresponding to T₃ standards (0-600 ng/100 ml), at 15 and 120 min, it is apparent that a 15-min equilibration period with the antibody alone is sufficient. Similar results were noted with human sera, which also indicates that equilibration with antibody up to 2 hr at 37°C apparently does not result in T₃ formation from T₄ present in sera. The

zero value (no T₃) at 15 min was the same as that noted at 120 min after equilibration, indicating that even prolonged equilibration at 37°C does not compromise the integrity of labeled T₃ antiserum, as shown by the absence of spontaneous release of ¹²⁵I-T₃ from labeled antiserum.

Variation in interval of resin sponge incubation. When ¹²⁵I-T₃ uptake corresponding to various T₃ standards was compared at 15, 30, 45, and 60 min after sponge incubation, the 30-min incubation provided the best linear response up to 400 ng.

Effect on T₃-RIA of elapsed period after TCA-NaOH addition. Replicate T₃ standards were extracted with TCA-NaOH for 2 min and left at room temperature for 0, 30, 60, and 120 min, after which labeled T₃ antiserum was added and the assay completed. The values for zero and T₃ standards at all these intervals were the same, showing that in human serum TCA-NaOH releases T₃ from T₃-binding proteins instantaneously.

In another experiment, TCA-NaOH was added to two T₄ standards (15 and 20 µg/100 ml) and two hyperthyroid sera, and the samples were left in a 37°C water bath 1-4 hr, followed by addition of ¹²⁵I-T₃-labeled antiserum and completion of the assay. The ¹²⁵I-T₃-uptake values noted in T₄ standards and in serum samples at 1 hr were similar to those noted at 4 hr, again showing that even with prolonged TCA-NaOH extraction at 37°C under highly alkaline conditions, T₄ present in sera is not converted to T₃, since any new T₃ formed would be expected to react with ¹²⁵I-T₃-labeled immune serum and thus increase the sponge ¹²⁵I-T₃ uptake.

Effect on T₃-RIA of moderate excess of TCA-NaOH. A twofold excess of TCA-NaOH extractant had no deleterious effect on the assay. Use of 0.1-0.3 ml extractant in the assay resulted in standard curves that could be superimposed.

Serum T₃ extraction efficiency of TCA-NaOH. The ¹²⁵I-T₃ uptakes, 30 min after sponge incubation in the extraction medium containing ¹²⁵I-T₃-labeled sera and in labeled controls, are shown in Table 2. The ¹²⁵I-T₃ uptake in buffer was 92%, and the failure to obtain 100% within this interval (i.e., 30 min) can be attributed partly to the low temperature (0-1°C) used for sponge incubation. The control with gamma-globulin (which does not actively bind T₃) showed 90% uptake. Since protein concentrations in sera and gamma-globulin were approximately equal, T₃ extraction recovery values were compared with the latter (Table 2). Since there is 96% (mean) abstraction of radioactivity by a secondary binding site such as the resin (Table 2), in the presence of specific and high-affinity T₃-binding protein, such as the antibody, virtually all unbound T₃ in the system,

TABLE 2. SERUM T₃ EXTRACTION EFFICIENCY OF TCA-NaOH*

¹²⁵ I-T ₃ -labeled sera and controls	Sponge ¹²⁵ I-T ₃ uptake at 30 min† (%)	Extraction recovery‡ (%)
Controls		
Buffer	92.3 ± 1.01	
Gamma-globulin	90.4 ± 1.12	
Sera		
Hypothyroid	88.3 ± 0.74	97.7
Normal	87.6 ± 1.27	96.9
Pregnancy	85.5 ± 1.43	94.6
Hyperthyroid	86.2 ± 1.24	95.3

* Based on recovery of ¹²⁵I-T₃ from ¹²⁵I-T₃-labeled serum, or labeled controls, as determined by sponge ¹²⁵I-T₃ uptake. Data based on ten different samples in each category.

† Mean ± 1 standard deviation.

‡ Expressed in reference to gamma-globulin.

TABLE 3. COMPARISON OF T₃-RIA VALUES IN SERA DENATURED THERMALLY (60°C) OR BY TCA-NaOH

Sera	T ₃ concentration (ng/100 ml)	
	Thermally denatured	TCA-NaOH denatured
Euthyroid	178	190
	156	154
	170	162
	177	175
	240	235
	110	123
Hypothyroid	48	62
	55	50
	73	83
	40	39
Pregnancy	212	207
	172	185
	206	204
	190	195
Hyperthyroid	625	650
	262	260
	300	270
	440	455

after treatment of serum by TCA-NaOH, should react with antibody almost instantaneously. Therefore, after TCA-NaOH extraction in the assay, T₃ antibody clearly becomes the only binding agent, and serum T₃-binding proteins no longer compete or bind T₃. Additional corroborative investigations are noted below.

Comparison of TBG inactivation by thermal denaturation and TCA-NaOH on T₃-RIA. The direct evidence for lack of TBG interference in T₃-RIA was obtained in experiments where TBG was inactivated by thermal denaturation (12). Instead of

adding 0.2 ml of TCA-NaOH as done in our procedure, 0.2 ml of phosphate buffer was added to serum samples as well as T₃ standards, followed by addition of ¹²⁵I-T₃-labeled antiserum. The samples were left in a 60–65°C water bath for 3 hr, after which they were transferred to a refrigerator. Following overnight cold (6°C) equilibration, the assay was completed in the usual manner. In some experiments, assays were completed immediately after thermal inactivation, i.e., without overnight cold equilibration. No differences in T₃ values were found, whether or not thermally inactivated sera were subjected to overnight cold equilibration. Accordingly most assays were completed immediately after thermal inactivation. The values noted are compared with the T₃ values obtained by our regular procedure using TCA-NaOH to denature serum proteins (Table 3). The values obtained in all sera by either procedure are virtually the same, showing that the presence of TBG in unextracted serum does not interfere with T₃-RIA, and that TCA-NaOH denaturation* of TBG is as effective as thermal denaturation.

Sensitivity, precision, accuracy, and validity of T₃-RIA. The sensitivity of the technique was at least 25 ng/100 ml (or 12.5 pg/tube), since the use of this T₃ standard consistently caused a significant displacement of label from ¹²⁵I-T₃-labeled antibody. Concentrations of T₃ between 0 and 25 ng/100 ml were not tested. Interassay precision of 20 determinations in normal (142 ng/100 ml), hypothyroid (60 ng/100 ml), and hyperthyroid (330 ng/100 ml) sera showed coefficients of variation of 9.5%, 13.6%, and 5.6%, respectively. In determining accuracy, T₃ concentrations added were allowed to equilibrate with sera overnight prior to the assay. Table 4 shows the T₃-RIA values found before and after exogenous T₃ addition. At all levels of added T₃ there was virtually complete recovery in all sera despite TBG variation, the range being 93–109%.

To study T₄ cross-reaction, T₄ standards (5 and 10 μg/100 ml) were used in the assay, and the equivalent T₃ values were 7.5 and 45 ng/100 ml, respectively. Thus, the cross-reactions were 0.1% and 0.4%, respectively. Essentially similar results were obtained with 15- and 20-μg T₄ standards, and the average cross-reaction was approximately 0.4%. Negligible interaction with the antibody was found

* The effectiveness of TCA-NaOH in denaturing TBG in serum under the assay conditions described was also checked by TBG radioimmunoassay (Nichols Institute for Endocrinology, Wilmington, Calif.). The TBG concentration in a serum pool before denaturation was 3.6 mg/100 ml, whereas TBG was not detectable after TCA-NaOH extraction.

TABLE 4. T₃ RECOVERY IN T₃-RIA PROCEDURE

Sera	(A) Endogenous serum T ₃ (ng/100 ml)	(B) T ₃ added exogenously (ng/100 ml)	(C)	Recovery (%) (C — A)/B
			Serum T ₃ after exogenous T ₃ addition (ng/100 ml)	
Normal				
No. 1	108	250	365	102
No. 2	150	250	388	95
Hypothyroid				
No. 1	50	300	353	101
No. 2	35	250	300	106
Hyperthyroid				
No. 1	300	500	768	94
No. 2	400	300	680	93
Pregnancy				
No. 1	200	800	1070	109
No. 2	150	800	1020	109

with 3:5 diiodothyronine, monoiodotyrosine, and diiodotyrosine. The T₃-RIA determinations in eight-fold dilution of T₃ standards, in T₃-free plasma, or in saline agreed well with the values of undiluted standards (Table 5). Similar results were noted in the serum sample subjected to fourfold dilution.

T₃-RIA in normal and abnormal thyroid states. The T₃-RIA values (mean in ng/100 ml ± 1 s.d., with the ranges) were 142 ± 29.8 (82–217) in 92 normal subjects; 220 ± 82.1 (110–348) in 16 pregnant women; 55 ± 32.1 (8–128) in 19 hypothyroid subjects; and 411 ± 188 (222–970) in 18 hyperthyroid subjects. The T₃ values in normal and hyperthyroid subjects were clearly separated, but some overlap was found between normal and hypothyroid values, as noted by several other investigators (5,8,19). Among other possible factors, it has been suggested that excess thyroid-stimulating hormone (TSH) secretion in early primary hypothyroidism may stimulate T₃ in preference to T₄ (19,20), and the evidence from recent in vitro investigations of TSH effects on T₄-to-T₃ ratios (21) seems compatible with this suggestion.

DISCUSSION

The results make it clear that the RIA technique described for T₃ determination is an accurate, sensitive, reliable, and valid procedure. Furthermore, it has completely avoided such cumbersome and time-consuming steps as pre-extraction, centrifugation, column preparation, transfer of assay reactants for free- and bound-hormone separation, etc. The assay can be completed in the same tube in about 1 hr. For elic-

TABLE 5. EFFECT OF DILUTION ON T₃-RIA*

Dilution factor	T ₃ Standard 1		T ₃ Standard 2		Serum	
	in T ₃ -free plasma	in saline	in T ₃ -free plasma	in saline	in T ₃ -free plasma	in saline
Undiluted	3000	3000	2000	2000	500	500
1:1 (1/2)	2950	2810	1810	1900	425	460
1:3 (1/4)	2900	2960	1900	1825	410	—
1:7 (1/8)	2975	2460	1820	—	—	—

* Values (ng/100 ml) obtained with diluted sera are corrected for appropriate dilution.

ing T₃ antibodies, T₃-albumin conjugate was satisfactory, and the antibody titer is fairly comparable to that of other workers who have used similar conjugated immunogen. In addition, the negligible T₄ cross-reaction with T₃ antibody shows not only that T₃ can be measured satisfactorily, but also the absence of measurable T₄-to-T₃ conversion in the assay.

In the RIA of T₃ in unextracted serum, various solvents have been used to prevent serum-protein binding of T₃ (principally by TBG). These include ANS (4), tetrachlorothyronine (3), dilantin (7), sodium salicylate (5), and ethylmercurithiosalicylate (merthiolate, Ref. 2). Dinitrophenol and diazepam have also been used in some studies. While successful assays can be developed by the careful use of blocking agents, some workers have only reported varying degrees of success (9,13), whereas others (12,16) have expressed strong reservations regarding the use of many of these TBG-blocking agents. Alternative techniques of TBG inactivation and T₃ extraction have also been resorted to, e.g., thermal denaturation, enzymatic cleavage, etc. Use of TCA-NaOH extractant as in the present assay offers certain attractive features: (A) the denaturation of TBG is instantaneous; (B) despite the rapidity of extraction, TCA-NaOH facilitates fairly uniform T₃ recovery from all samples; (C) as the ability of serum proteins to bind T₃ is lost, there is no active or residual binding of T₃ tracer—in contrast with TBG-blocking assays, where the potential for such binding does exist.

Serum T₃ concentration in euthyroid subjects as noted in the present study (142 ng/100 ml) is virtually the same as that noted by several groups of investigators (3,6-9,11) and is closely comparable to the values in the majority of T₃-RIAs. Our mean value is also in close agreement with that of Patel and Burger (8), who used serum extracts in their assay, and that of Surks et al (6), who used column chromatography to separate proteins. In addition, the mean value found by this assay is close to that observed in gas-liquid chromatography (137 ng/

100 ml), as described by Mitsuma et al (3), who made appropriate corrections for T₄-to-T₃ conversion in their technique. In the extreme, our mean T₃ values are 35% lower than those reported by Gharib et al (2) and 48% higher than those reported by Alexander and Jennings (10). The discrepancy between results has been attributed to a variety of causes, some of which are variation in iodine concentration among subjects; the differing TBG-blocking agents used in the assay; the widely varying techniques for separating free and bound hormone; and such other experimental conditions as sensitivity, specificity of the antibody, etc. Sterling and Milch (12) suggested that the order of discrepancies in T₃ concentrations between workers is similar to that noted when one reads the values from standard curves prepared in buffer or T₃-free serum. In influencing T₃ values the importance of the nature of the protein solution used to prepare T₃ standards has also been stressed (15). Moreover, recent investigations show that age could be an important factor, since T₃ concentration has been reported to be reduced in subjects with increasing age (19). Finally, Savoie et al (14) have suggested that different T₃ antisera may varyingly cross-react with reverse T₃ in serum, which may contribute to apparent differences in mean T₃ values in normal subjects as noted in different investigations.

ACKNOWLEDGMENTS

The author is indebted to various personnel at Abbott Laboratories who extended cooperation in this study, particularly I. D. Smith and J. P. Miller for providing materials and equipment. The author is also indebted to numerous physicians and other scientific colleagues for providing serum specimens and supporting clinical diagnoses, and in particular, the assistance of W. L. Florsheim, H. W. Wahner, G. A. Hagen, V. V. Row, R. Volpe, I. B. Perlstein, and R. Burstein is gratefully acknowledged.

REFERENCES

1. GHARIB H: Triiodothyronine, physiological and clinical significance. *JAMA* 227: 302-304, 1974
2. GHARIB H, RYAN RJ, MAYBERRY WE, et al: Radioimmunoassay for triiodothyronine (T₃): I. Affinity and

specificity of the antibody for T₃. *J Clin Endocrinol Metab* 33: 509-516, 1971

3. MITSUMA T, NIHEI N, GERSHENGORN MC, et al: Serum triiodothyronine: Measurements in human serum by radioimmunoassay with corroboration by gas-liquid chromatography. *J Clin Invest* 50: 2679-2688, 1971

4. CHOPRA IJ, HO RS, LAM R: An improved radioimmunoassay of triiodothyronine in serum: Its application to clinical and physiological studies. *J Lab Clin Med* 80: 729-739, 1972

5. LARSEN PR: Direct immunoassay of triiodothyronine in human serum. *J Clin Invest* 51: 1939-1949, 1972

6. SURKS MI, SCHADLOW AR, OPPENHEIMER JH: A new radioimmunoassay for plasma L-triiodothyronine: Measurements in thyroid disease and in patients maintained on hormonal replacement. *J Clin Invest* 51: 3104-3113, 1972

7. LIEBLICH J, UTIGER RD: Triiodothyronine radioimmunoassay. *J Clin Invest* 51: 157-166, 1972

8. PATEL YC, BURGER HG: A simplified radioimmunoassay for triiodothyronine. *J Clin Endocrinol Metab* 36: 187-190, 1973

9. SEKADDE CB, SLAUNWHITE WR, ACETO T: Rapid radioimmunoassay of triiodothyronine. *Clin Chem* 19: 1016-1021, 1973

10. ALEXANDER NM, JENNINGS JF: Radioimmunoassay of serum triiodothyronine on small, reusable Sephadex columns. *Clin Chem* 20: 1353-1361, 1974

11. RASTOGI GK, SAWHNEY RC: Tri-iodothyronine radioimmunoassay in unextracted serum. *Indian J Med Res* 62: 225-232, 1974

12. STERLING K, MILCH PO: Thermal inactivation of thyroxine-binding globulin for direct radioimmunoassay of triiodothyronine in serum. *J Clin Endocrinol Metab* 38: 866-875, 1974

13. EASTMAN CJ, CORCORAN JM, EKINS RP, et al: The radioimmunoassay of triiodothyronine and its clinical application. *J Clin Pathol* 28: 225-230, 1975

14. SAVOIE JC, BELLABARBA D, THOMOPOULOS P, et al: Serum T₃-RIA. *Ann Endocrinol (Paris)* 36: 171-172, 1975

15. BURGER A, SAKOFF C, STAEHEL V, et al: Radioimmunoassays of 3,5,3'-triiodo-L-thyronine with and without a prior extraction step. *Acta Endocrinol* 80: 58-69, 1975

16. HUFNER M, HESCH RD: A comparison of different compounds for TBG-blocking used in radioimmunoassay for tri-iodothyronine. *Clin Chim Acta* 44: 101-107, 1973

17. PREMACHANDRA BN, IBRAHIM II: Use of thyroxine-binding antibodies for rapid estimation of total thyroxine and free thyroxine index in human sera. In *Radioimmunoassay and Related Procedures in Medicine*, vol 2, Vienna, IAEA, 1974, pp 141-160

18. OLIVER GC, PARKER BM, BRASFIELD DL, et al: The measurement of digitoxin in human serum by radioimmunoassay. *J Clin Invest* 47: 1035-1042, 1968

19. UTIGER RD: Serum triiodothyronine in man. *Ann Rev Med* 25: 289-302, 1974

20. PAIN RW: In vitro testing of thyroid function: A review. *Pathology* 7: 1-12, 1975

21. CHAPMAN RS, MALAN PG: Thyroidal stimulation by thyrotrophin: Differential release of tri-iodothyronine relative to thyroxine. *J Endocrinol* 65: 17P, 1975

ANNOUNCEMENT

The Education and Research Foundation of the Society of Nuclear Medicine welcomes applications for two of its projects.

- **Medical Student Fellowship Program:** This educational project is designed to stimulate interest among medical students in the United States and Canada in the field of nuclear medicine. It will make it possible for interested and qualified students to spend elective quarters and summers in active nuclear medicine laboratories working and associating with experts in the field. Maximum grant: \$1,000. Application letters in duplicate, including a description of the project and budget, should be sent to the President of the Foundation, c/o Society of Nuclear Medicine, 475 Park Avenue South, New York, New York 10116.
- **Pilot Research Grants in Nuclear Medicine:** The goal of this research support is to provide limited sums of money to scientists to support deserving projects that are pilot in nature. It is hoped that it will make it possible for nuclear medicine scientists to apply for small sums of money for clinical and basic research and to get a decision within a short time following application. The grants will not support salaries, major equipment purchases or travel, but are designed to provide essential materials so that innovative ideas can be quickly tested. Maximum grant \$1,000. Application forms are available from the President of the Foundation, c/o Society of Nuclear Medicine, 475 Park Avenue South, New York, New York 10016.